Research and Publication Ethics
All manuscripts should be written with strict adherence to the "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals" of International Committee of Medical Journal Editors (http://www.icmje.org/recommendations/, updated August 2013. Issues of ethical misconduct, plagiarism, and duplicate/redundant publication will be judged and dealt with according to the "Good Publication Practice Guidelines for Medical Journals, 2nd" (http://www.kamje.or.kr). For all studies involving human subjects, the principles embodied in the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) should be upheld, informed consent must be obtained from all participants, and must be approved by a recognized Institutional Review Board (IRB) or research ethics committee. The editor may request submission of copies of informed consents from human subjects in clinical studies or IRB approval documents. Experiments involving animals should comply with the NIH guidelines for the use of laboratory animals (http://grants.nih.gov/grants/olaw/guide-for-the-care-and-useof-laboratory-animals.pdf) and/ or be reviewed by an appropriate committee (e.g., Institutional Animal Care and Use Committee, IACUC) to ensure the ethical treatment of animals in research. KSION will follow the guidelines by the Committee on Publication Ethics (COPE, http://publicationethics.org/) for settlement of any misconduct.
KSION follows the "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals" (http://www.icmje.org/recommendations/, updated August 2013) and the "Good Publication Practice Guidelines for Medical Journals, 2nd" (http://www.kamje.or.kr). Authorship is credited to those who have direct involvement in the study and have made significant contributions to (a) substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (b) drafting the work or revising it critically for important intellectual content; AND (c) final approval of the version to be published; AND (d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved as recommended by ICMJE. The primary investigator is designated the first author of the study, unless contested by the other authors. The corresponding author is directly responsible for communication and revision of the submitted manuscript. All persons who have made substantial contribution, but who are not eligible as authors should be named in the acknowledgments. In the case of change of authorship, a written explanation must be submitted. Change in either the first author or the corresponding author requires approval by the editorial board, and any changes in the other authors require approval by the editor-in-chief.
Conflict of Interest
The corresponding author of an article is asked to inform the editor of the authors' potential conflicts of interest possibly influencing their interpretation of data. A potential conflict of interest must be disclosed during the online submission process on the appropriate web page. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems based on the "ICMJE Uniform Disclosure Form for Potential Conflicts of Interest" (http://www.icmje.org/coi_disclosure.pdf). The editor will decide whether the information on the conflict should be included in the published paper. Before publishing such information, the editor will consult with the corresponding author. In particular, all sources of funding for a study should be explicitly stated.
Originality and Duplicate Publication
All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the editorial board. If duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed. There will also be penalties for the authors.
• Duty of ethical committee
The Ethical committee deliberates on the research ethics raised about the publication of the journal related papers (The original article, case report, brief communication, and review article et al) and the research activities of the members of the society.
Ethical committee should suspicious of a submitted manuscripts regarding any type of research misconduct, including double publication, or plagiarism with intent to deceive by the authors.
• Pursuing misconduct (Treatment about research ethical violations)
Editors are often the first recipients of suspicions about studies that may involve misconduct or other ethical violations. If editors suspect ethical violation by authors, reviewers, editorial staff, or other editors then they have a duty to take action. Any deviation from this code of conduct could be misconduct and should be pursued in the first instance through the journal’s complaints procedure. The Editor-in-chief will reject a manuscript if research misconduct is suspected. If the matter is unresolved, a complaint may be referred to the Editorial board.
Issues of ethical misconduct, plagiarism, and duplicate/redundant publication will be judged and dealt with according to the "Good publication Practice Guidelines for Medical Journals" (http://kamje.or.kr).
For the policies on the research and publication ethics not stated in this instructions, International standards for editors and authors (http://publicationethics.org/resources/internationalstandards-for-editors-and-authors) can be applied.